Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompanieshVIVO plc

hVIVO plc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
5.55 GBX 0.00(0%)
Last update at 2026-10-27T16:41:00Z
VOLUME
724338
Market Cap
48.53M
P/E
7.05

Momentum Score

…

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.40
Low
5.70
High
52 Week Price Range
4.30
Low
19.28
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.55
Dividend Yield
2.90%
Revenue TTM
54.47M
Revenue Per Share
0.08
Gross Profit TTM
10.70M
Debt / Equity
0.29
ROE
12.87%
Net Debt
-31.28M
ROCE
25.00%
Diluted EPS TTM
0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax 13.29M 11.15M -0.36M 0.28M -11.16M
Net income 10.65M 16.11M -0.78M -0.07M -10.79M
Selling general administrative 26.13M 24.17M 23.54M 17.86M 10.96M
Gross profit 62.73M 10.41M 48.48M 35.90M 19.88M
Reconciled depreciation 3.56M 2.72M - - -
Ebit 14.24M 11.30M 6.84M 0.24M -8.66M
Ebitda 17.80M 14.02M 9.77M 2.80M -6.61M
Depreciation and amortization 3.56M 2.72M 2.93M 2.56M 2.05M
Operating income 12.86M 10.10M 6.02M 0.59M -10.44M
Other operating expenses 49.87M 48.56M 42.34M 36.57M 29.16M
Interest expense 1.11M 0.18M 0.13M 0.23M 0.37M
Tax provision 2.64M -4.97M - - -
Interest income 1.83M 1.18M - - -
Net interest income 0.72M 1.00M - - -
Income tax expense 2.64M -4.97M 0.41M 0.35M -0.37M
Total revenue 62.73M 56.04M 48.48M 36.86M 20.60M
Total operating expenses 49.87M 45.94M 42.34M 35.60M 28.43M
Cost of revenue - 45.63M - 0.96M 0.73M
Total other income expense net 0.43M 1.04M -6.39M -0.31M -0.72M
Net income from continuing ops 10.65M 16.11M - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 88.89M 83.23M 51.38M 42.27M 48.55M
Intangible assets 0.10M 0.07M 0.42M 0.62M 0.53M
Other current assets 1.29M 1.41M - - -
Total liab 44.22M 48.90M 31.16M 21.59M 26.25M
Total stockholder equity 44.67M 34.33M 20.22M 20.68M 22.30M
Other current liab 26.67M 31.91M 26.24M 16.35M 16.47M
Common stock 0.68M 0.68M 0.67M 0.67M 0.67M
Capital stock 0.68M 0.68M - - -
Retained earnings 48.81M 38.68M 24.46M 25.21M -17.99M
Good will 5.60M 5.60M 5.60M 5.60M 5.60M
Cash 44.18M 36.97M 28.44M 15.69M 19.20M
Total current liabilities 31.91M 35.18M 29.77M 20.69M 24.03M
Current deferred revenue - 24.94M - 16.35M 16.48M
Net debt -31.28M -24.44M -26.88M -12.55M -14.41M
Short term debt 2.51M 0.37M 0.83M 2.29M 2.60M
Short long term debt total 12.90M 12.53M 1.56M 3.15M 4.80M
Other stockholder equity -4.81M -5.03M -4.92M -5.20M 39.62M
Total current assets 60.23M 52.00M 42.23M 25.34M 30.04M
Net receivables 13.96M 13.20M - - -
Inventory 0.80M 0.43M 0.50M 0.66M 0.95M
Accounts payable 1.88M 2.09M 2.70M 2.06M 4.95M
Accumulated other comprehensive income - 1.31M - - -
Non currrent assets other 0.00M 5.67M - 7.00M 7.08M
Non current assets total 28.66M 31.22M 9.15M 16.94M 18.50M
Capital lease obligations 12.90M 12.53M - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total cashflows from investing activities -0.66M -5.18M - - -
Net borrowings - 0.00M - - -
Total cash from financing activities -2.40M -4.70M -1.83M -1.20M 13.04M
Net income 13.29M 11.15M -0.36M 0.28M -11.16M
Change in cash 7.21M 8.53M 12.75M -3.51M 18.17M
Begin period cash flow 36.97M 28.44M 15.69M 19.20M 1.04M
End period cash flow 44.18M 36.97M 28.44M 15.69M 19.20M
Total cash from operating activities 10.34M 17.24M 15.98M -1.56M 4.17M
Issuance of capital stock 0.00M 0.52M - - -
Depreciation 3.56M 2.72M 2.93M 2.56M 2.05M
Other cashflows from investing activities 1.76M - - - -
Dividends paid 1.36M 3.05M - - -
Change to inventory -0.38M 0.07M 0.17M 0.29M -0.03M
Change to account receivables 1.75M -1.16M - - -
Other cashflows from financing activities -1.05M -2.17M -1.54M -1.19M -3.63M
Capital expenditures 2.46M 5.18M 1.36M 0.74M 1.09M
Change in working capital -3.71M 4.10M 7.01M -1.77M 11.58M
Stock based compensation 0.84M 0.57M 0.28M 0.03M 0.24M
Other non cash items -3.63M -1.30M 6.12M -2.66M 1.46M
Free cash flow 7.88M 12.06M 14.62M -2.30M 3.08M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HVO
hVIVO plc		 -
-%		 5.55 7.05 18.32 0.89 1.01 0.69 2.93
IDHC
Integrated Diagnostics Holdings PLC		 -
-%		 0.48 0.20 12.89 3.33 6.89 3.22 8.79
ABDX
Abingdon Health Plc		 -
-%		 9.00 - 53.19 2.19 3.19 1.81 -0.25
CLBX
CelLBxHealth plc		 -
-%		 0.60 - - 7.05 1.50 6.07 -1.62
GDR
genedrive plc		 0.03
2.44%		 1.05 - 12.38 12.99 10.61 16.54 -6.05

Profile*

hVIVO plc

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

40 Bank Street, London, United Kingdom, E14 5NR

44 20 7756 1300

https://www.hvivo.com

301

Name Title Year Born
Dr. Yamin Mohammed Khan Ph.D. CEO & Director 1969
Mr. Stephen Mark Pinkerton CFO & Executive Director 1963
Mr. Andrew Catchpole Chief Scientific Officer NA
Ms. Teja Marathe-Sarvadikar Head of Quality Assurance NA
Dr. Thomas Forst M.D. Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…